Catalyst Pharmaceuticals Inc (OQ:CPRX)

Business Focus: Biopharmaceuticals

Mar 27, 2024 08:03 am ET
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today...
Mar 21, 2024 09:31 am ET
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
NEW YORK, March 21, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRAX, SHOT, CPRX, ACET, and EXAI.
Mar 13, 2024 07:55 am ET
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne Muscular Dystrophy...
Mar 05, 2024 08:03 am ET
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat...
Feb 28, 2024 06:03 pm ET
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported financial results for the fourth quarter and full year 2023 and provided a business update. "In 2023, Catalyst delivered exceptional financial performance...
Feb 27, 2024 08:03 am ET
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with A
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and...
Feb 21, 2024 09:00 am ET
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with...
Feb 14, 2024 08:03 am ET
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Jan 09, 2024 04:05 pm ET
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of shares of its common stock. The Company sold 10,000,000 shares of its common stock in the offering at...
Jan 05, 2024 08:02 am ET
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross...
Jan 04, 2024 04:49 pm ET
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock. Catalyst also intends to grant the underwriters a 30-day option...
Dec 18, 2023 06:30 am ET
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its...
Dec 05, 2023 08:03 am ET
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024. Catalyst has ranked an impressive 4th out of 100...
Dec 04, 2023 08:03 am ET
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Mr. Kalb will report directly to...
Nov 16, 2023 08:05 am ET
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced...
Nov 08, 2023 04:11 pm ET
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX) today reported financial results for the third quarter of 2023 and provided a corporate update. "Our strong results in the third quarter reflect our exceptional...
Nov 02, 2023 10:37 am ET
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced...
Oct 30, 2023 08:03 am ET
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced...
Oct 26, 2023 03:19 pm ET
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals ("Santhera") has obtained U.S. Food and Drug Administration ("FDA") approval for AGAMREE® (vamorolone) oral suspension 40 mg/mL for...
Oct 23, 2023 08:03 am ET
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will...
Oct 19, 2023 08:03 am ET
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced...
Oct 16, 2023 08:03 am ET
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement...
Oct 13, 2023 08:03 am ET
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that the U.S. Food and Drug Administration ("FDA" or "Agency") has accepted for review the Company's supplemental New Drug Application ("sNDA") to increase the...
Sep 18, 2023 08:03 am ET
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick...
Aug 16, 2023 10:56 am ET
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Aug 14, 2023 08:05 am ET
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Aug 09, 2023 04:17 pm ET
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update. "We are extremely pleased with the remarkable progress we achieved during...
Jul 25, 2023 08:03 am ET
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that Patrick J. McEnany, Catalyst’s Co-Founder, Chairman, and Chief Executive Officer ("CEO") has informed the Board of Directors ("Board") of his intention to...
Jul 24, 2023 08:03 am ET
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will...
Jul 19, 2023 06:00 am ET
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced the completion of its acquisition from Santhera Pharmaceuticals Holdings ("Santhera") of an exclusive license for North America for vamorolone, a potential...
Jun 20, 2023 06:00 am ET
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Catalyst...
Jun 01, 2023 08:03 am ET
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported positive momentum for the second quarter of 2023 and reaffirmed its full-year 2023 total revenue guidance of between $375 million and $385 million, representing...
May 30, 2023 08:03 am ET
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today...
May 15, 2023 11:43 am ET
Thinking about buying stock in JetBlue Airways, Hecla Mining, Catalyst Pharmaceuticals, Energy Transfer, or Ford?
NEW YORK, May 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JBLU, HL, CPRX, ET, and F.
May 10, 2023 04:27 pm ET
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
Catalyst Pharmaceuticals, Inc. ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and provided a corporate update. "Catalyst had an excellent start to the year driven by the sustained organic...
May 09, 2023 08:03 am ET
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported...
May 01, 2023 08:03 am ET
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced...
Apr 24, 2023 08:03 am ET
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will...
Apr 20, 2023 08:03 am ET
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Mar 15, 2023 04:11 pm ET
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial...
Mar 08, 2023 11:20 am ET
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Mar 01, 2023 08:03 am ET
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Feb 22, 2023 08:03 am ET
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
Catalyst Pharmaceuticals, Inc., (“Catalyst”) (Nasdaq: CPRX) today announced that the Company will ring the Nasdaq Closing Bell on February 28, 2023, in recognition of International Rare Disease Day to help shed light on the important unmet need for...
Feb 07, 2023 08:03 am ET
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
Catalyst Pharmaceuticals, Inc., ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Jan 25, 2023 08:03 am ET
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has...
Jan 23, 2023 01:25 pm ET
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today commented on the FDA's...
Jan 23, 2023 08:03 am ET
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has...
Dec 19, 2022 04:10 pm ET
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has...
Nov 09, 2022 04:11 pm ET
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial...
Nov 07, 2022 08:03 am ET
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has...
Oct 25, 2022 08:03 am ET
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will...
Sep 29, 2022 11:18 am ET
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that the U.S....
Sep 13, 2022 09:31 am ET
Thinking about buying stock in Core & Main, Catalyst Pharmaceuticals, Ironsource, Clovis Oncology, or Oncternal Therapeutics?
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNM, CPRX, IS, CLVS, and ONCT.
Sep 12, 2022 07:30 pm ET
Catalyst Pharmaceuticals Set to Join S&P SmallCap 600
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Catalyst Pharmaceuticals Inc. (NASD: CPRX) will replace Mantech International Corp. (NASD: MANT) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, September 15. The Carlyle Group Inc. (NASD: CG) is acquiring ManTech International in a transaction expected to be completed soon pending final conditions.
Sep 09, 2022 08:03 am ET
Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick...
Aug 24, 2022 08:03 am ET
Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick...
Aug 09, 2022 04:25 pm ET
Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial...
Jul 26, 2022 08:03 am ET
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will...
Jul 12, 2022 06:00 am ET
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has...
May 17, 2022 08:03 am ET
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick...
May 10, 2022 04:11 pm ET
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial...
Apr 25, 2022 08:03 am ET
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will...
Mar 16, 2022 04:20 pm ET
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial...
Mar 11, 2022 08:03 am ET
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare...
Mar 08, 2022 08:03 am ET
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Mar 03, 2022 09:20 am ET
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Mar 02, 2022 08:03 am ET
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare...
Feb 24, 2022 08:03 am ET
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Feb 17, 2022 08:03 am ET
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced...
Feb 07, 2022 08:03 am ET
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Feb 03, 2022 08:03 am ET
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Jan 28, 2022 01:46 pm ET
Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judge
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Jan 10, 2022 08:03 am ET
Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Jan 04, 2022 07:30 am ET
Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Dec 06, 2021 07:00 am ET
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Nov 15, 2021 04:15 pm ET
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Nov 09, 2021 04:14 pm ET
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Oct 25, 2021 08:03 am ET
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Sep 30, 2021 12:08 pm ET
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Sep 17, 2021 08:03 am ET
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Sep 10, 2021 08:03 am ET
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases,...
Aug 16, 2021 08:03 am ET
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Aug 09, 2021 04:39 pm ET
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Jul 26, 2021 08:03 am ET
Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Jul 19, 2021 08:03 am ET
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Jul 06, 2021 08:03 am ET
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Jun 29, 2021 08:03 am ET
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Jun 28, 2021 04:30 pm ET
Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Jun 28, 2021 08:03 am ET
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Jun 03, 2021 03:09 pm ET
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
MISSISSAUGA, ON, June 3, 2021 /CNW/ - Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada's approv
Jun 03, 2021 01:20 pm ET
Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
May 19, 2021 08:03 am ET
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
May 10, 2021 05:29 pm ET
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
May 03, 2021 08:05 am ET
Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,...
Mar 22, 2021 08:03 am ET
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases,...
Mar 15, 2021 05:26 pm ET
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases,...
Mar 04, 2021 11:00 am ET
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Feb 22, 2021 08:03 am ET
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Jan 06, 2021 08:07 am ET
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Nov 09, 2020 05:20 pm ET
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases,...
Nov 02, 2020 08:03 am ET
Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Oct 19, 2020 06:03 am ET
Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Oct 06, 2020 11:15 am ET
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Sep 29, 2020 04:40 pm ET
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment...
Aug 26, 2020 09:40 am ET
KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Aug 18, 2020 08:03 am ET
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Aug 11, 2020 06:00 am ET
Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine"
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Aug 10, 2020 04:15 pm ET
Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases,...
Aug 06, 2020 08:03 am ET
Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Aug 03, 2020 04:15 pm ET
Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Aug 03, 2020 08:03 am ET
Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Jul 31, 2020 11:10 am ET
Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit against the FDA has filed a Report and Recommendation in which she recommends to the District Judge handling the case...
Jun 23, 2020 08:03 am ET
Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Jun 01, 2020 08:03 am ET
Catalyst Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
May 11, 2020 04:17 pm ET
Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases,...
May 04, 2020 08:03 am ET
Catalyst Pharmaceuticals to Hold First Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 12th, 2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Apr 08, 2020 06:00 am ET
Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Mar 16, 2020 05:26 pm ET
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases,...
Mar 10, 2020 08:03 am ET
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Feb 27, 2020 08:03 am ET
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Feb 26, 2020 08:03 am ET
Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Feb 06, 2020 08:03 am ET
Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Feb 04, 2020 08:02 am ET
Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Jan 06, 2020 08:03 am ET
Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Nov 26, 2019 08:03 am ET
Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Nov 12, 2019 04:39 pm ET
Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...
Nov 11, 2019 05:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX
Pomerantz LLP is investigating claims on behalf of investors of Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (NASDAQ: CPRX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Nov 01, 2019 12:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX
Pomerantz LLP is investigating claims on behalf of investors of Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (NASDAQ: CPRX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Oct 31, 2019 08:03 am ET
Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Oct 30, 2019 06:03 am ET
Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing innovative therapies for people with ultra-rare debilitating, chronic neuromuscular and neurological diseases, today announced top-line...
Sep 25, 2019 08:02 am ET
Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Sep 23, 2019 02:55 pm ET
Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources
Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) is commenting on today's trading activity in its common stock and on the current state of its capital resources. The Company is reporting that it is not aware of any information about the Company's...
Sep 13, 2019 09:31 am ET
Thinking about buying stock in AbbVie, Aurora Cannabis, Catalyst Pharmaceuticals, Fibrocell Science, or MER Telemanagement Solutions?
NEW YORK, Sept. 13, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, ACB, CPRX, FCSC, and MTSL.
Sep 13, 2019 06:03 am ET
Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019. The Company believes that the culmination of an offering at the current...
Sep 11, 2019 04:19 pm ET
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to an...
Aug 28, 2019 08:03 am ET
Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Aug 07, 2019 04:18 pm ET
Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported...
Aug 01, 2019 08:03 am ET
Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Jul 31, 2019 08:03 am ET
Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Jun 12, 2019 08:47 am ET
Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration (FDA) and several related parties challenging the recent approval of a new drug application and related drug...
Jun 04, 2019 08:03 am ET
Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
May 30, 2019 08:03 am ET
Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
May 13, 2019 06:03 am ET
Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported...
May 06, 2019 08:03 am ET
Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 13th, 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Apr 08, 2019 07:30 am ET
Market Trends Toward New Normal in Catalyst Pharmaceuticals, Allete, Noodles, Uranium Energy, Materion, and Altisource Portfolio Solutions S.A — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), Allete, Inc. (NYSE:ALE),...
Mar 18, 2019 04:20 pm ET
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported...
Mar 11, 2019 08:03 am ET
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Feb 28, 2019 08:03 am ET
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Feb 26, 2019 08:03 am ET
Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Feb 21, 2019 09:00 am ET
Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic, neuromuscular and neurological diseases, today...
Feb 05, 2019 08:03 am ET
Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Jan 04, 2019 08:03 am ET
Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Dec 18, 2018 11:40 am ET
Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Dec 11, 2018 07:30 am ET
Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Dev
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sabre Corporation (NASDAQ:SABR), Catalyst Pharmaceuticals, Inc....
Dec 03, 2018 08:03 am ET
Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases today announced...
Nov 29, 2018 06:03 am ET
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Nov 27, 2018 04:12 pm ET
Catalyst Pharmaceuticals Announces Firdapse® (amifampridine) New Drug Application Continues Under Review
Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) today reports that no decision has yet been received from the Food and Drug Administration with respect to the company’s new drug application for Firdapse. The company reported that a contractor working...
Nov 07, 2018 04:19 pm ET
Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial...
Oct 31, 2018 08:03 am ET
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, November 8th, 2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Oct 10, 2018 07:30 am ET
Market Trends Toward New Normal in AllianceBernstein Holding, Five9, Simpson Manufacturing, Green Plains, Catalyst Pharmaceuticals, and Commercial Vehicle Group — Emerging Consolidated Expectations, A
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AllianceBernstein Holding L.P. (NYSE:AB), Five9, Inc. (NASDAQ:FIVN),...
Sep 20, 2018 08:03 am ET
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Aug 29, 2018 08:03 am ET
Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Aug 20, 2018 08:03 am ET
Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Aug 07, 2018 04:20 pm ET
Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial...
Aug 06, 2018 08:03 am ET
Catalyst Pharmaceuticals Expands Commercial Leadership Team
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Aug 01, 2018 08:03 am ET
Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 8th, 2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Aug 01, 2018 07:30 am ET
New Research Coverage Highlights Ladder Capital, Gibraltar Industries, Norwegian Cruise Line, Wolverine World Wide, Catalyst Pharmaceuticals, and Radius Health — Consolidated Revenues, Company Growth,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ladder Capital Corp (NYSE:LADR), Gibraltar Industries, Inc. (NASDAQ:ROCK),...
Jun 13, 2018 08:03 am ET
Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
Jun 12, 2018 08:00 am ET
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit...
May 31, 2018 08:03 am ET
Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced...
May 29, 2018 08:03 am ET
Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced today...
May 09, 2018 04:13 pm ET
Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial...
May 02, 2018 08:03 am ET
Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, May 10th, 2018
CORAL GABLES, Fla., May 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it...
Apr 24, 2018 08:03 am ET
Catalyst Pharmaceuticals Introduces New Corporate Website
CORAL GABLES, Fla., April 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today is pleased to...
Apr 20, 2018 08:10 am ET
Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health — Future Expectations, Projections Moving into 2018
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clean Energy Fuels Corp. (NASDAQ:CLNE), Catalyst...
Mar 29, 2018 08:19 am ET
Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla., March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its submission of...
Mar 14, 2018 04:13 pm ET
Mar 12, 2018 08:03 am ET
Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
CORAL GABLES, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has...
Mar 08, 2018 08:04 am ET
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018
CORAL GABLES, Fla., March 08, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will...
Feb 28, 2018 08:03 am ET
Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018
CORAL GABLES, Fla., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the company’s support...
Feb 15, 2018 07:35 am ET
Detailed Research: Economic Perspectives on Carbo Ceramics, Consolidated Communications, Catalyst Pharmaceuticals, Office Depot, ImmunoGen, and Cedar Realty Trust — What Drives Growth in Today's Compe
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carbo Ceramics, Inc. (NYSE:CRR), Consolidated Communications...
Feb 12, 2018 08:03 am ET
Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®
CORAL GABLES, Fla., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the results of...
Feb 07, 2018 08:03 am ET
Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
CORAL GABLES, Fla., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Patrick...
Nov 30, 2017 02:07 pm ET
Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Public Offering
CORAL GABLES, Fla., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 16,428,572 shares of its common stock...
Nov 30, 2017 08:20 am ET
Analysis: Positioning to Benefit within Office Depot, ImmunoGen, Cedar Realty Trust, Carbo Ceramics, Consolidated Communications, and Catalyst Pharmaceuticals — Research Highlights Growth, Revenue, an
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Office Depot, Inc. (NASDAQ:ODP), ImmunoGen,...
Nov 28, 2017 09:17 am ET
Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) today announced the pricing of its previously announced underwritten public offering. The Company announced that it is selling 14,285,715 shares of its common stock in the public offering at an offering price of $3.50 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of common stock to cover over-allotments, if any. All of the shares in the offering are being sold by Catalyst.
Nov 27, 2017 04:03 pm ET
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announced today that it has commenced an underwritten public offering of 11 million shares of its common stock. Catalyst also intends to grant the underwriters...
Nov 27, 2017 06:30 am ET
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome
-- Treatment with Firdapse Achieved Statistical Significance for Co-Primary Endpoints and Secondary Endpoint --
Nov 21, 2017 08:03 am ET
Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy (SMA)
CORAL GABLES, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the initiation of...
Nov 08, 2017 04:41 pm ET
Aug 09, 2017 04:29 pm ET
Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2017 and provided a corporate update....
Aug 01, 2017 08:03 am ET
Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017
CORAL GABLES, Fla., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that it will release second quarter 2017 financial results after market close on Wednesday, August 9, 2017. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Thursday, August 10th, 2017 to discuss the financial results and to provide a corporate update....
Jun 26, 2017 08:03 am ET
Catalyst Pharmaceuticals Joins Russell 3000 Index
CORAL GABLES, Fla., June 26, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that the company has been added to the broad-market Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted June 9....
May 10, 2017 04:35 pm ET
Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2017....
Mar 15, 2017 04:31 pm ET
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
New Positive Phase 2/3 Data for Firdapse® Treating Myasthenia Gravis Patients with anti-MuSK Antibodies...
Feb 27, 2017 08:03 am ET
Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
CORAL GABLES, Fla., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), (Catalyst) a biopharmaceutical company focused on  developing  and  commercializing  innovative  therapies  for  people  with  rare  debilitating diseases, today announced that  it  has  joined  forces  with  30  million  Americans  and  health  care  advocates around the world for Rare Disease Day® on February 28. Rare Disease Day is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges they present to patients a...
Feb 09, 2017 04:05 pm ET
Catalyst Pharmaceuticals Announces Participation at SunTrust Robinson Humphrey’s 2017 Orphan Drug Day
CORAL GABLES, Fla., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that management will be attending the SunTrust Robinson Humphrey’s 2017 Orphan Drug Day on February 14, 2017 in New York City....
Nov 21, 2016 08:03 am ET
Catalyst Pharmaceuticals to Participate in the 28th Annual Piper Jaffray Healthcare Conference
CORAL GABLES, Fla., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will participate as part of the Underdiscovered Neuro-Innovators Panel at the 28th Annual Piper Jaffray Healthcare Conference being held at Lotte New York Palace, NY, November 29-30.  The panel will take place Tuesd...
Nov 09, 2016 04:20 pm ET
Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2016 and provided a corporate update....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.